Last month, Harmony Biosciences Holdings Inc. (HRMY), a dedicated pharmaceutical firm specializing in innovative therapies for rare neurological diseases, revealed robust preliminary, unaudited net product revenues of $201 million for the fourth quarter of fiscal 2024 and $714 million for the full year.
HRMY’s impressive performance paves the way for a dynamic 2025, packed with value-driving milestones each quarter. With a sharp focus on maximizing its neuroscience pipeline, the company enters the year with unstoppable momentum, charting a clear course toward sustained growth and a potential $3 billion in future net revenue.
